Lyman, Stewart D.
Amgen - Seattle Office,
United States
2025 Rank: 73748
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Developmental Biology
Rank in SubField 1: 2043 out of 166615 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 73748 | 79907 |
| Total Cites | 10456 | 11352 |
| H-index | 54 | 55 |
| Hm-index | 14 | 15 |
| Number of Single Authored Papers | 2 | 2 |
| Total Cites to Single Authored Papers | 140 | 148 |
| Number of Single+First Authored Papers | 20 | 20 |
| Total Cites to Single+First Authored Papers | 1768 | 1913 |
| Number of Single+First+Last Authored Papers | 38 | 38 |
| Total Cites to Single+First+Last Authored Papers | 3451 | 3730 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 6547 | 6876 |
| Ratio of Total Citations to Distinct Citing Papers | 1.60 | 1.65 |
| Self-Citation Percentage |
7.89%
|
|
Lyman, Stewart D.
Amgen Incorporated,
United States
2024 Rank: 68350
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Developmental Biology
Rank in SubField 1: 1948 out of 157372 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 68350 | 74069 |
| Total Cites | 10305 | 11191 |
| H-index | 54 | 55 |
| Hm-index | 14 | 15 |
| Number of Single Authored Papers | 2 | 2 |
| Total Cites to Single Authored Papers | 138 | 146 |
| Number of Single+First Authored Papers | 20 | 20 |
| Total Cites to Single+First Authored Papers | 1728 | 1872 |
| Number of Single+First+Last Authored Papers | 38 | 38 |
| Total Cites to Single+First+Last Authored Papers | 3392 | 3669 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 6443 | 6771 |
| Ratio of Total Citations to Distinct Citing Papers | 1.60 | 1.65 |
| Self-Citation Percentage |
7.92%
|
|
Lyman, Stewart D.
Amgen Incorporated,
United States
2023 Rank: 62943
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Developmental Biology
Rank in SubField 1: 1841 out of 147556 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 62943 | 68360 |
| Total Cites | 10181 | 11062 |
| H-index | 54 | 55 |
| Hm-index | 14 | 15 |
| Number of Single Authored Papers | 2 | 2 |
| Total Cites to Single Authored Papers | 136 | 144 |
| Number of Single+First Authored Papers | 20 | 20 |
| Total Cites to Single+First Authored Papers | 1700 | 1844 |
| Number of Single+First+Last Authored Papers | 38 | 38 |
| Total Cites to Single+First+Last Authored Papers | 3340 | 3616 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 6342 | 6669 |
| Ratio of Total Citations to Distinct Citing Papers | 1.61 | 1.66 |
| Self-Citation Percentage |
7.96%
|
|
Lyman, Stewart D.
Amgen Incorporated,
United States
2022 Rank: 56221
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Developmental Biology
Rank in SubField 1: 1724 out of 138599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 56221 | 61359 |
| Total Cites | 10013 | 10893 |
| H-index | 54 | 55 |
| Hm-index | 14 | 15 |
| Number of Single Authored Papers | 2 | 2 |
| Total Cites to Single Authored Papers | 135 | 143 |
| Number of Single+First Authored Papers | 20 | 20 |
| Total Cites to Single+First Authored Papers | 1681 | 1825 |
| Number of Single+First+Last Authored Papers | 38 | 38 |
| Total Cites to Single+First+Last Authored Papers | 3293 | 3569 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 6211 | 6538 |
| Ratio of Total Citations to Distinct Citing Papers | 1.61 | 1.67 |
| Self-Citation Percentage |
8.08%
|
|
Lyman, Stewart D.
Amgen Incorporated,
United States
2021 Rank: 53593
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Developmental Biology
Rank in SubField 1: 1641 out of 127911 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 53593 | 57974 |
| Total Cites | 9850 | 10722 |
| H-index | 53 | 55 |
| Hm-index | 14 | 15 |
| Number of Single Authored Papers | 2 | 2 |
| Total Cites to Single Authored Papers | 134 | 142 |
| Number of Single+First Authored Papers | 20 | 20 |
| Total Cites to Single+First Authored Papers | 1655 | 1799 |
| Number of Single+First+Last Authored Papers | 39 | 39 |
| Total Cites to Single+First+Last Authored Papers | 3239 | 3511 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 6111 | 6435 |
| Ratio of Total Citations to Distinct Citing Papers | 1.61 | 1.67 |
| Self-Citation Percentage |
8.13%
|
|
Lyman, Stewart D.
Amgen Incorporated,
United States
2020 Rank: 48261
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Biochemistry & Molecular Biology
Rank in SubField 1: 1485 out of 108509 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 48261 | 51692 |
| Total Cites | 9641 | 10511 |
| H-index | 52 | 55 |
| Hm-index | 14 | 15 |
| Number of Single Authored Papers | 2 | 2 |
| Total Cites to Single Authored Papers | 131 | 139 |
| Number of Single+First Authored Papers | 20 | 20 |
| Total Cites to Single+First Authored Papers | 1613 | 1756 |
| Number of Single+First+Last Authored Papers | 39 | 39 |
| Total Cites to Single+First+Last Authored Papers | 3169 | 3442 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 5968 | 6289 |
| Ratio of Total Citations to Distinct Citing Papers | 1.62 | 1.67 |
| Self-Citation Percentage |
8.28%
|
|
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.